Immunomedics, Inc. (IMMU) Announces Initiation Of Phase 3 Clinical Trial Of Clivatuzumab Tetraxetan In Patients With Pancreatic Cancer
1/10/2014 9:25:41 AM
MORRIS PLAINS, N.J., Jan. 9, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced first patient dosing in the Company's Phase III registration study of its pancreatic cancer drug, yttrium-90 (90Y)-clivatuzumab tetraxetan.
Help employers find you! Check out all the jobs and post your resume.
comments powered by